Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.1)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 353–359

doi: 10.17219/acem/81538

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Adropin and irisin: New biomarkers of cardiac status in patients with end-stage renal disease? A preliminary study

Małgorzata Kałużna1,A,B,C,D,F, Krzysztof Pawlaczyk2,A,C,D,E,F, Krzysztof Schwermer2,B,C,D,F, Krzysztof Hoppe2,B,F, Magdalena Człapka-Matyasik3,B,C,D,E,F, Aisha Yusuf Ibrahim2,D,E,F, Nadia Sawicka-Gutaj1,B,E,F, Andrzej Minczykowski4,C,D,E,F, Katarzyna Ziemnicka1,A,C,D,E,F, Andrzej Oko2,E,F, Marek Ruchała1,A,D,E,F

1 Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poland

2 Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, Poland

3 Department of Human Nutrition and Hygiene, Poznan University of Life Sciences, Poland

4 Department of Cardiology – Intensive Therapy, Poznan University of Medical Sciences, Poland

Abstract

Background. The new polypeptide hormones adropin and irisin have a broad impact on human metabolism and energy homeostasis. They could be potential biomarkers of cardiac injury. In end-stage renal disease (ESRD), the clinical importance of adropin and irisin is yet to be investigated.
Objectives. The aim of this study was to determine the relationship between these peptides and cardiac status in ESRD patients.
Material and Methods. Seventy-nine ESRD patients on hemodialysis (HD), peritoneal dialysis (PD) or after renal transplantation (Tx), and 40 healthy, ageand sex-matched controls (CON) were included in this study. Serum concentrations of adropin and irisin were measured with enzyme-linked immunosorbent assay (ELISA). Cardiac status was estimated by transthoracic echocardiography and the plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT).
Results. The levels of irisin were significantly lower in HD patients as compared to CON. During HD sessions, the concentrations of adropin did not change significantly, whereas the concentrations of irisin increased with borderline significance. Positive correlations were evident between adropin concentration and cTnT as well as NT-proBNP. Adropin was also correlated with left ventricular systolic internal diameter (LVIDs) (r = 0.375, p = 0.045) and relative wall thickness (RWT) (r = −0.382, p = 0.034). Irisin was correlated with right ventricular diameter (RVd) (r = −0.363, p = 0.045). No correlations were found between irisin and adropin, and blood pressure (BP) measurements.
Conclusion. Adropin could be a new candidate marker of cardiac dysfunction in HD patients. The cause of low levels of irisin found in HD patients is still unclear. These 2 myokines should be further investigated as potential prognostic markers of cardiac status in HD patients.

Key words

hemodialysis, end-stage renal disease, irisin, adropin, cardiac status

References (43)

  1. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–586.
  2. Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function: Newly discovered association. Peptides. 2014;60:51–55.
  3. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchala M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol. 2016;67(5):476–480.
  4. Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides. 2014;56:94–110.
  5. Butler AA, Tam CS, Stanhope KL, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012;97(10):3783–3791.
  6. Chen M, Ouyang F, Zhou S. Adropin as a novel energy factor likely has the ability to regulate blood pressure. Med Hypotheses. 2015;85(2):234.
  7. Colaianni G, Cuscito C, Mongelli T, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A. 2015;112(39):12157–12162.
  8. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468–481.
  9. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751–758.
  10. Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011;50(15):1523–1527.
  11. Aydin S, Kuloglu T, Aydin S, et al. Elevated adropin: A candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides. 2014;58:91–97.
  12. Celik A, Balin M, Kobat MA, et al. Deficiency of a new protein associated with cardiac syndrome X called adropin. Cardiovasc Ther. 2013;31(3):174–178.
  13. Goetze JP, Albrethsen J. Adropin: A new regulatory peptide in cardiovascular endocrinology. Regul Pept. 2014;190–191:41–42.
  14. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190–191:46–49.
  15. Zhang C, Zhao L, Xu W, et al. Correlation of serum adropin level with coronary artery disease [in Chinese]. Zhonghua Yi Xue Za Zhi. 2014;94(16):1255–1257.
  16. Zhao LP, Xu WT, Wang L, et al. Serum adropin level in patients with stable coronary artery disease. Heart Lung Circ. 2015;24(10):975–979.
  17. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161–1164.
  18. Lovren F, Pan Y, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;122(11 Suppl):S185–192.
  19. Bostrom P, Wu J, Jędrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468.
  20. Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, et al. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutr Diabetes. 2014;4(2):e110.
  21. Vamvini MT, Aronis KN, Panagiotou G, et al. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol. 2013;169(6):829–834.
  22. Xie C, Zhang Y, Tran TD, et al. Irisin controls growth, intracellular Ca2+ signals, and mitochondrial thermogenesis in cardiomyoblasts. PLoS One. 2015;10(8):e0136816.
  23. Zhang W, Chang L, Zhang C, et al. Central and peripheral irisin differentially regulate blood pressure. Cardiovasc Drugs Ther. 2015;29(2):121–127.
  24. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, Garatachea N, Lucia A. Serum irisin levels, precocious myocardial infarction and healthy exceptional longevity. Am J Med. 2014;127(9):888–890.
  25. Lecker SH, Zavin A, Cao P, et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail. 2012;5(6):812–818.
  26. Kuloglu T, Aydin S, Eren MN, et al. Irisin: A potentially candidate marker for myocardial infarction. Peptides. 2014;55:85–91.
  27. Ebert T, Focke D, Petroff D, et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol. 2014;170(4):501–506.
  28. Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013;8(5):e64025.
  29. Aydin S, Kuloglu T, Aydin S, et al. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: Cardiac muscle produces more irisin than skeletal muscle. Peptides. 2014;52:68–73.
  30. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013;380(1–2):73–81.
  31. Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108.
  32. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270.
  33. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–458.
  34. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107–133.
  35. Wang SP, Gao YL, Liu G, et al. Molecular cloning, characterization and expression of the energy homeostasis-associated gene in piglet. J Zhejiang Univ Sci B. 2015;16(6):524–532.
  36. Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20(7):1394–1402.
  37. Martin MW. Treatment of congestive heart failure – a neuroendocrine disorder. J Small Anim Pract. 2003;44(4):154–160.
  38. Oh HJ, Lee MJ, Lee HS, et al. NT-proBNP: Is it a more significant risk factor for mortality than troponin T in incident hemodialysis patients? Medicine (Baltimore). 2014;93(27):e241.
  39. Schwermer K, Hoppe K, Radziszewska D, et al. N-terminal proB-type natriuretic peptide as a marker of hypervolemia and predictor of increased mortality in patients on hemodialysis. Pol Arch Med Wewn. 2015;125(7–8):560–569.
  40. Hoppe K, Schwermer K, Kłysz P, et al. Cardiac troponin T and hydration status as prognostic markers in hemodialysis patients. Blood Purif. 2015;40(2):139–145.
  41. St-Onge M-P, Shechter A, Shlisky J, et al. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014;22(4):1056–1063.
  42. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013;41(4):375–380.
  43. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia and atherosclerosis. Cell Metab. 2011;14(5):575–585.
© Wroclaw Medical University